| Abiraterone in metastatic prostate cancer without previous chemotherapy CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ... New England Journal of Medicine 368 (2), 138-148, 2013 | 3192 | 2013 |
| Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal … RJ Motzer, MD Michaelson, BG Redman, GR Hudes, G Wilding, RA Figlin, ... Journal of Clinical Oncology 24 (1), 16-24, 2006 | 2137 | 2006 |
| Sunitinib in patients with metastatic renal cell carcinoma RJ Motzer, BI Rini, RM Bukowski, BD Curti, DJ George, GR Hudes, ... Jama 295 (21), 2516-2524, 2006 | 1610 | 2006 |
| Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ... Journal of Clinical Oncology 34 (12), 1402, 2016 | 1306 | 2016 |
| Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy A Ravaud, RJ Motzer, HS Pandha, DJ George, AJ Pantuck, A Patel, ... New england journal of medicine 375 (23), 2246-2254, 2016 | 790 | 2016 |
| Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial TK Choueiri, S Halabi, BL Sanford, O Hahn, MD Michaelson, MK Walsh, ... Journal of Clinical Oncology 35 (6), 591, 2017 | 789 | 2017 |
| Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate JB Nelson, SP Hedican, DJ George, AH Reddi, S Piantadosi, ... Nature medicine 1 (9), 944-949, 1995 | 781 | 1995 |
| Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers AJ Armstrong, MS Marengo, S Oltean, G Kemeny, RL Bitting, JD Turnbull, ... Molecular cancer research 9 (8), 997-1007, 2011 | 768 | 2011 |
| Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer G Agnelli, DJ George, AK Kakkar, W Fisher, MR Lassen, P Mismetti, ... New England Journal of Medicine 366 (7), 601-609, 2012 | 641 | 2012 |
| Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate … WK Kelly, S Halabi, M Carducci, D George, JF Mahoney, WM Stadler, ... Journal of Clinical Oncology 30 (13), 1534, 2012 | 502 | 2012 |
| Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma BI Rini, MD Michaelson, JE Rosenberg, RM Bukowski, JA Sosman, ... Journal of Clinical Oncology 26 (22), 3743-3748, 2008 | 488 | 2008 |
| Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial AJ Armstrong, S Halabi, T Eisen, S Broderick, WM Stadler, RJ Jones, ... The Lancet Oncology 17 (3), 378-388, 2016 | 411 | 2016 |
| Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free … TK Choueiri, C Hessel, S Halabi, B Sanford, MD Michaelson, O Hahn, ... European journal of cancer 94, 115-125, 2018 | 385 | 2018 |
| Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes RH Vonderheide, SM Domchek, JL Schultze, DJ George, KM Hoar, ... Clinical Cancer Research 10 (3), 828-839, 2004 | 354 | 2004 |
| Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma L Ellis, Y Pan, GK Smyth, DJ George, C McCormack, R Williams-Truax, ... Clinical Cancer Research 14 (14), 4500-4510, 2008 | 346 | 2008 |
| Oral relugolix for androgen-deprivation therapy in advanced prostate cancer ND Shore, F Saad, MS Cookson, DJ George, DR Saltzstein, R Tutrone, ... New England Journal of Medicine 382 (23), 2187-2196, 2020 | 340 | 2020 |
| Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model PK Majumder, JJ Yeh, DJ George, PG Febbo, J Kum, Q Xue, R Bikoff, ... Proceedings of the National Academy of Sciences 100 (13), 7841-7846, 2003 | 334 | 2003 |
| Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study AJ Armstrong, S Halabi, J Luo, DM Nanus, P Giannakakou, ... Journal of Clinical Oncology 37 (13), 1120, 2019 | 307 | 2019 |
| Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480 DJ George, S Halabi, TF Shepard, NJ Vogelzang, DF Hayes, EJ Small, ... Clinical cancer research 7 (7), 1932-1936, 2001 | 294 | 2001 |
| Sunitinib efficacy against advanced renal cell carcinoma RJ Motzer, MD Michaelson, J Rosenberg, RM Bukowski, BD Curti, ... The Journal of urology 178 (5), 1883-1887, 2007 | 261 | 2007 |
